Literature DB >> 20375164

Enhancerless cytomegalovirus is capable of establishing a low-level maintenance infection in severely immunodeficient host tissues but fails in exponential growth.

Jürgen Podlech1, Rares Pintea, Kai A Kropp, Annette Fink, Niels A W Lemmermann, Katja C Erlach, Elena Isern, Ana Angulo, Peter Ghazal, Matthias J Reddehase.   

Abstract

Major immediate-early transcriptional enhancers are genetic control elements that act, through docking with host transcription factors, as a decisive regulatory unit for efficient initiation of the productive virus cycle. Animal models are required for studying the function of enhancers paradigmatically in host organs. Here, we have sought to quantitatively assess the establishment, maintenance, and level of in vivo growth of enhancerless mutants of murine cytomegalovirus in comparison with those of an enhancer-bearing counterpart in models of the immunocompromised or immunologically immature host. Evidence is presented showing that enhancerless viruses are capable of forming restricted foci of infection but fail to grow exponentially.

Entities:  

Mesh:

Year:  2010        PMID: 20375164      PMCID: PMC2876661          DOI: 10.1128/JVI.00419-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

Review 1.  To be or not to be active: the stochastic nature of enhancer action.

Authors:  S Fiering; E Whitelaw; D I Martin
Journal:  Bioessays       Date:  2000-04       Impact factor: 4.345

2.  The human cytomegalovirus major immediate-early enhancer determines the efficiency of immediate-early gene transcription and viral replication in permissive cells at low multiplicity of infection.

Authors:  Hiroki Isomura; Mark F Stinski
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Characterization of the major immediate-early polypeptides encoded by murine cytomegalovirus.

Authors:  G M Keil; M R Fibi; U H Koszinowski
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

4.  A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus.

Authors:  K Dorsch-Häsler; G M Keil; F Weber; M Jasin; W Schaffner; U H Koszinowski
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

5.  Identification and characterization of novel murine cytomegalovirus M112-113 (e1) gene products.

Authors:  Gina M Ciocco-Schmitt; Zaruhi Karabekian; Earl W Godfrey; Richard M Stenberg; Ann E Campbell; Julie A Kerry
Journal:  Virology       Date:  2002-03-01       Impact factor: 3.616

6.  An essential role of the enhancer for murine cytomegalovirus in vivo growth and pathogenesis.

Authors:  Peter Ghazal; Martin Messerle; Kent Osborn; Ana Angulo
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  Rat cytomegalovirus major immediate-early enhancer switching results in altered growth characteristics.

Authors:  G R Sandford; L E Brock; S Voigt; C M Forester; W H Burns
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

8.  Role of murine cytomegalovirus US22 gene family members in replication in macrophages.

Authors:  Carine Ménard; Markus Wagner; Zsolt Ruzsics; Karina Holak; Wolfram Brune; Ann E Campbell; Ulrich H Koszinowski
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

9.  Synergism between the components of the bipartite major immediate-early transcriptional enhancer of murine cytomegalovirus does not accelerate virus replication in cell culture and host tissues.

Authors:  Kai A Kropp; Christian O Simon; Annette Fink; Angélique Renzaho; Birgit Kühnapfel; Jürgen Podlech; Matthias J Reddehase; Natascha K A Grzimek
Journal:  J Gen Virol       Date:  2009-06-24       Impact factor: 3.891

10.  Mouse cytomegalovirus immediate-early protein 1 binds with host cell repressors to relieve suppressive effects on viral transcription and replication during lytic infection.

Authors:  Qiyi Tang; Gerd G Maul
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  5 in total

Review 1.  Viral latency drives 'memory inflation': a unifying hypothesis linking two hallmarks of cytomegalovirus infection.

Authors:  Christof K Seckert; Marion Griessl; Julia K Büttner; Sabine Scheller; Christian O Simon; Kai A Kropp; Angélique Renzaho; Birgit Kühnapfel; Natascha K A Grzimek; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2012-09-19       Impact factor: 3.402

Review 2.  Principles for studying in vivo attenuation of virus mutants: defining the role of the cytomegalovirus gH/gL/gO complex as a paradigm.

Authors:  Jürgen Podlech; Matthias J Reddehase; Barbara Adler; Niels A W Lemmermann
Journal:  Med Microbiol Immunol       Date:  2015-03-18       Impact factor: 3.402

3.  The activator protein 1 binding motifs within the human cytomegalovirus major immediate-early enhancer are functionally redundant and act in a cooperative manner with the NF-{kappa}B sites during acute infection.

Authors:  Elena Isern; Montse Gustems; Martin Messerle; Eva Borst; Peter Ghazal; Ana Angulo
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

4.  Reversible inhibition of murine cytomegalovirus replication by gamma interferon (IFN-γ) in primary macrophages involves a primed type I IFN-signaling subnetwork for full establishment of an immediate-early antiviral state.

Authors:  Kai A Kropp; Kevin A Robertson; Garwin Sing; Sara Rodriguez-Martin; Mathieu Blanc; Paul Lacaze; Muhamad F B Noor Hassim; Mizanur R Khondoker; Andreas Busche; Paul Dickinson; Thorsten Forster; Birgit Strobl; Mathias Mueller; Stipan Jonjic; Ana Angulo; Peter Ghazal
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

5.  A temporal gate for viral enhancers to co-opt Toll-like-receptor transcriptional activation pathways upon acute infection.

Authors:  Kai A Kropp; Wei Yuan Hsieh; Elena Isern; Thorsten Forster; Eva Krause; Wolfram Brune; Ana Angulo; Peter Ghazal
Journal:  PLoS Pathog       Date:  2015-04-09       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.